Quarterly report pursuant to Section 13 or 15(d)

Recent Developments, Liquidity and Management???s Plans (Details Narrative)

v3.22.2.2
Recent Developments, Liquidity and Management’s Plans (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Apr. 16, 2022
Apr. 16, 2021
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Aug. 17, 2022
Dec. 31, 2020
Mar. 23, 2020
Goodwill     $ 10,498,539           $ 10,498,539   $ 10,498,539      
Fair market value price per share                       $ 4.25    
Cash on hand     309,926           309,926   555,967      
Marketable securities     6,774,381           6,774,381   11,003,071      
Loss from operations     3,693,741     $ 5,467,281     11,451,818 $ 26,649,321        
Working capital     6,296,506           6,296,506          
Stockholders' equity     18,327,047 $ 16,118,343 $ 19,622,140 25,891,924 $ 31,074,335 $ (8,346,738) 18,327,047 25,891,924 23,647,174   $ (5,257,034)  
Accumulated deficit     90,013,386           90,013,386   78,561,568      
Net cash provided by operating activities                 10,021,664 14,704,008        
Net loss     3,693,741 $ 3,636,043 $ 4,122,034 5,467,281 $ 18,092,336 $ 3,089,704 11,451,818 26,649,321        
Non cash share based compensation     $ 352,417         581,663 15,036,051        
Increase in trade and other payables                 $ 730,683 $ (3,234,057)        
Restricted Stock Units (RSUs) [Member]                            
Non cash share based compensation   $ 979,758                        
Contribution Agreement [Member] | Premas Biotech PVT Ltd [Member]                            
Amount owed on investments                     1,500,000      
Payments to investments                     $ 1,200,000      
Merger Agreement [Member]                            
Issuance of post reverse stock split   28,553,307                        
Exchange ratio percentage   77.05%                        
Percentage of common stock 49.68%                          
Merger Agreement [Member] | Pre-funded Warrants [Member]                            
Warrants to purchase   986,486                        
Cystron Biotech LLC [Member] | Membership Interest Purchase Agreement [Member]                            
Acquired membership interests, percentage                           100.00%
MYMD Pharmaceuticals, Inc., [Member] | Merger Agreement [Member]                            
Business acquisition description   Upon completion of the Merger and the transactions contemplated in the Merger Agreement, the Company issued 28,553,307 post reverse stock split shares of Company Common Stock to the former stakeholders of pre-Merger MyMD Florida at the Exchange Ratio. Upon completion of the Merger and the transactions contemplated in the Merger Agreement, the former stakeholders of pre-Merger MyMD Florida held approximately 77.05% of the Company’s Common Stock outstanding on a fully diluted basis, assuming the exercise in full of the pre-funded warrants to purchase 986,486 shares of Company Common Stock and including 4,188,315 shares of Company Common Stock underlying options to purchase shares of pre-Merger MyMD Florida Common Stock assumed by the company at closing and after adjustments based on the Company’s net cash at closing. Holders of pre-Merger common stock of the Company held approximately 22.95% of the outstanding equity of the Company. Also upon completion of the Merger and the transactions contemplated by the Merger Agreement, the Company assumed 4,188,315 MyMD Florida stock options subject to certain terms contained in the Merger Agreement (including, but not limited to, the amendment of such stock option to extend the term of such stock option for a period expiring on April 16, 2023, the second-year anniversary of the Merger                        
Akers Biosciences, Inc [Member]                            
Goodwill   $ 10,498,539                        
Pre market capitalization   42,477,346                        
Tangible asset   $ 31,978,807                        
Common shares outstanding   8,335,627                        
Akers Biosciences, Inc [Member] | Restricted Stock Units (RSUs) [Member]                            
Vested restricted stock unit   263,026                        
Fair market value price per share   $ 4.94